Patents by Inventor Christopher F. O'Brien

Christopher F. O'Brien has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for the administration of certain VMAT2 inhibitors
    Patent number: 11654142
    Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-?-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,1 1b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered digoxin.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: May 23, 2023
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Christopher F. O'Brien, Haig P. Bozigian
  • Methods for the administration of certain VMAT2 inhibitors
    Patent number: 11439629
    Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-?-3-isobutyl-9,10-dimethoxy-1, 3,4, 6,7,11 b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is a CYP2D6 poor metabolizer.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: September 13, 2022
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Christopher F. O'Brien, Haig P. Bozigian
  • High dosage valbenazine formulation and compositions, methods, and kits related thereto
    Patent number: 11311532
    Abstract: Solid pharmaceutical compositions with high drug loading are provided. A formulation useful for the solid pharmaceutical composition includes valbenazine, or a pharmaceutically acceptable salt thereof, silicified microcrystalline cellulose, isomalt, hydroxypropyl methylcellulose, partially pregelatinized maize starch, and magnesium stearate.
    Type: Grant
    Filed: October 19, 2020
    Date of Patent: April 26, 2022
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Richard Alexander Moore, Jr., Gregory A. McClelland, Christopher F. O'Brien
  • TREATMENT OF HYPERKINETIC MOVEMENT DISORDERS
    Publication number: 20210196702
    Abstract: Methods for treating hyperkinetic diseases and disorders, such as tardive dyskinesia, are provided. In a certain embodiment, the potent VMAT2 inhibitor (+)?-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol ((+)?-HTBZ) is used in the methods described herein for treating a subject in need thereof.
    Type: Application
    Filed: September 15, 2020
    Publication date: July 1, 2021
    Inventors: Christopher F. O'Brien, Haig P. Bozigian
  • Methods for the administration of certain VMAT2 inhibitors
    Patent number: 11040029
    Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-?-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered a strong cytochrome P450 2D6 (CYP2D6) inhibitor.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: June 22, 2021
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Christopher F. O'Brien, Haig P. Bozigian
  • Methods for the Administration of Certain VMAT2 Inhibitors
    Publication number: 20210169862
    Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-?-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof to a patient in need thereof wherein the patient is being treated with a strong cytochrome P450 3A4 (CYP3A4) inducer.
    Type: Application
    Filed: December 17, 2020
    Publication date: June 10, 2021
    Inventors: Christopher F. O`Brien, Haig P. Bozigian
  • Methods for the administration of certain VMAT2 inhibitors
    Patent number: 11026931
    Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: June 8, 2021
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Grace S. Liang, Christopher F. O'Brien, Dao Tuyet Thai-Cuarto
  • Methods for the administration of certain VMAT2 inhibitors
    Patent number: 10993941
    Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-?-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient has mild, moderate, or severe hepatic impairment.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: May 4, 2021
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Christopher F. O'Brien, Haig P. Bozigian
  • Use of Valbenazine for Treating Schizophrenia or Schizoaffective Disorder
    Publication number: 20210113553
    Abstract: Provided herein are methods for treating schizophrenia or schizoaffective disorder by administering to a subject in need thereof (,S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester, or an isotopic variant thereof, or a pharmaceutically acceptable salt or polymorph thereof.
    Type: Application
    Filed: June 3, 2020
    Publication date: April 22, 2021
    Inventors: Christopher F. O`Brien, Dimitri E. Grigoriadis
  • Methods for the administration of certain VMAT2 inhibitors
    Patent number: 10952997
    Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-a-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered a strong cytochrome P450 3A4 (CYP3A4) inhibitor.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: March 23, 2021
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Christopher F. O'Brien, Haig P. Bozigian
  • Methods for the Administration of Certain VMAT2 Inhibitors
    Publication number: 20210046060
    Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-?-3-isobutyl-9,10-dimethoxy-1, 3,4, 6,7,11 b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is a CYP2D6 poor metabolizer.
    Type: Application
    Filed: October 26, 2020
    Publication date: February 18, 2021
    Inventors: Christopher F. O`Brien, Haig P. Bozigian
  • Methods for the Administration of Certain VMAT2 Inhibitors
    Publication number: 20210038593
    Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-?-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,1 1b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered digoxin.
    Type: Application
    Filed: October 20, 2020
    Publication date: February 11, 2021
    Inventors: Christopher F. O`Brien, Haig P. Bozigian
  • Methods for the administration of certain VMAT2 inhibitors
    Patent number: 10912771
    Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-?-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof to a patient in need thereof wherein the patient is being treated with a strong cytochrome P450 3A4 (CYP3A4) inducer.
    Type: Grant
    Filed: October 17, 2020
    Date of Patent: February 9, 2021
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Christopher F. O'Brien, Haig P. Bozigian
  • High Dosage Valbenazine Formulation and Compositions, Methods, and Kits Related Thereto
    Publication number: 20210030743
    Abstract: Solid pharmaceutical compositions with high drug loading are provided. A formulation useful for the solid pharmaceutical composition includes valbenazine, or a pharmaceutically acceptable salt thereof, silicified microcrystalline cellulose, isomalt, hydroxypropyl methylcellulose, partially pregelatinized maize starch, and magnesium stearate.
    Type: Application
    Filed: October 19, 2020
    Publication date: February 4, 2021
    Inventors: Richard Alexander Moore, JR., Gregory A. McClelland, Christopher F. O`Brien
  • High Dosage Valbenazine Formulation and Compositions, Methods, and Kits Related Thereto
    Publication number: 20210030744
    Abstract: Solid pharmaceutical compositions with high drug loading are provided. A formulation useful for the solid pharmaceutical composition includes valbenazine, or a pharmaceutically acceptable salt thereof, silicified microcrystalline cellulose, isomalt, hydroxypropyl methylcellulose, partially pregelatinized maize starch, and magnesium stearate.
    Type: Application
    Filed: October 19, 2020
    Publication date: February 4, 2021
    Inventors: Richard Alexander Moore, JR., Gregory A. McClelland, Christopher F. O`Brien
  • Methods for the Administration of Certain VMAT2 Inhibitors
    Publication number: 20210030742
    Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-?-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof to a patient in need thereof wherein the patient is being treated with a strong cytochrome P450 3A4 (CYP3A4) inducer.
    Type: Application
    Filed: October 17, 2020
    Publication date: February 4, 2021
    Inventors: Christopher F. O'Brien, Haig P. Bozigian
  • Methods for the administration of certain VMAT2 inhibitors
    Patent number: 10874648
    Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-a-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof to a patient in need thereof wherein the patient is being treated with a strong cytochrome P450 3A4 (CYP3A4) inducer.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: December 29, 2020
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Christopher F. O'Brien, Haig P. Bozigian
  • Methods for the administration of certain VMAT2 inhibitors
    Patent number: 10857137
    Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-?-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is a CYP2D6 poor metabolizer.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: December 8, 2020
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Christopher F. O'Brien, Haig P. Bozigian
  • Methods for the administration of certain VMAT2 inhibitors
    Patent number: 10857148
    Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-?-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered digoxin.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: December 8, 2020
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Christopher F. O'Brien, Haig P. Bozigian
  • METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS
    Publication number: 20200360354
    Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof.
    Type: Application
    Filed: August 3, 2020
    Publication date: November 19, 2020
    Inventors: Grace S. Liang, Christopher F. O`Brien, Dao Tuyet Thai-Cuarto